medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2005, Number 3

<< Back Next >>

Rev Esp Med Quir 2005; 10 (3)

Lineamientos para el manejo de la pérdida ósea secundaria a tratamiento para el cáncer

Signorelli S, Cruz J, Cuevas J, Febres R, Rodríguez R, Plazas R

Language: Spanish
References: 23
Page: 14-18
PDF size: 58.15 Kb.


ABSTRACT

An important Latin American meeting of Oncology experts was carried out in Miami, Florida, with the participation of oncologists from several countries in the region (Mexico, Brazil, Colombia, Argentina, Uruguay, Chile, etc.). This consensus meeting had the aim of sharing the current knowledge this clinicians and researchers have about different type of neoplasia and their clinical management updated according to the latest criteria and guidelines developed by the main research sites around the world, in order to present useful guidelines for physicians in their daily work. With the aim of exploring and discussing six different important oncological topics and establish some useful guidelines. this paper the cancer treatment induced bone loss (CTIBL) is discussed as one of the first and more important issues of cancer treatment, as long as it impacts severely the health and quality of life of the patients, promoting hypercalcemia, osteoporosis, pain and pathological fractures in several skeletal regions (hip, vertebrae, etc.), as well as the start of the bone metastasis development.


REFERENCES

  1. Siebler T, Shalet SM, Robson H. Effects of chemotherapy on bone metabolism and skeletal growth. Horm Res. 2002;58 Suppl 1:80-5.

  2. Bone Loss Accompanying Medical Therapies. The New England Journal of Medicine Volume 345:989-991, September 27, 2001 Number 13.

  3. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J M 2001;345:948-955.

  4. Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001;345:941-947.

  5. Stone K, Bauer DC, Black DM, et al. Hormonal predictors of bone loss in elderly women: a prospective study. J Bone Miner Res 1998;13:1167-1174.

  6. Ylikorkala O, Metsa-Heikkila M. Hormone replacement therapy in women with a history of breast cancer. Gynecol. Endocrinol. 2002 Dec;16(6):469-78.

  7. Mortimer JE. Hormone replacement therapy and beyond. The clinical challenge of menopausal symptoms in breast cancer survivors. Geriatrics. 2002 Sep;57(9):25-31.

  8. Goss PE, Ingle JN, Martino S, et al. A randomized trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer. NEJM 2003, 349:1793-1802.

  9. Coleman RE. Current and future status of adjuvant therapy for breast cancer. Cancer. 2003 Feb 1;97(3 Suppl):880-6.

  10. Mincey BA. Osteoporosis in women with breast cancer. Curr Oncol Rep. 2003 Jan;5(1):53-7.

  11. Lipton A. Bisphosphonate therapy in the oncology setting. Expert Opin Emerg Drugs. 2003 Nov;8(2):469-88.

  12. Vehmanen L, Saarto T, Elomaa I, et al. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer. 2001 Dec;37(18):2373-8.

  13. Higano CS. Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urol Oncol. 2003 Sep-Oct;21(5):392-8.

  14. Smith MR. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging. 2003;20(3):175-83.

  15. Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology. 2003 Feb;61(2 Suppl 1):32-8.

  16. Smith MR. Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer. Cancer Metastasis Rev. 2002;21(2):159-66.

  17. Higano CS. Management of bone loss in men with prostate cancer. J Urol. 2003 Dec;170(6 Pt 2):S59-63; discusión S64.

  18. Oefelein MG, Ricchiuti V, Conrad W, et al. Skeletal Fractures Negatively correlate with Overall Survival in Men with Prostate Cancer. The Journal of Urology Vol. 168, 1005-07, September 2002.

  19. Saad F, Gleason D, Murray R, et al. Zometa® is Effective in The Treatment of Bone Metastases from Prostate Cancer: Results of a large Phase III, Double-blind Randomized Trial. Presented at the American Urological Association Meeting on June 2, 2001.

  20. Saad F, Gleason D, Murray R, et al. Zoledronic Acid Significantly Reduces Fractures in Patients with Hormone Refractory Prostate Cancer Metastatic to Bone. Journal of Urology 2001; 167 (Suppl 4) 175, abstract 703.

  21. Saad F, Gleason D, Murray R, et al. A Randomized Placebo Controlled Trial of Zoledronic Acid in Patients with Hormone- Refractory Metastatic Prostate Carcinoma. Journal of The National Cancer Institute. Vol. 94, No. 19;pp:1458-68 October 2, 2002.

  22. Saad F. Bisphosphonates in Prostate Cancer: Where are We and Where Should We Go? Journal of the National Cancer Institute, Vol. 95, No. 17, 1262-1263, September 3, 2003

  23. Body JJ. Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis. Expert Opin Pharcamother. 2003 Apr;4(4):567-80




2020     |     www.medigraphic.com